Tenaya Therapeutics

The first patient has been dosed in the phase 1b RIDGE-1 trial evaluating Tenaya Therapeutics’ TN-401, an AAV-based gene therapy for PKP2-associated ARVC. The patient received a dose of 3x10^13 vg/kg at UCSF, with two more patients to be treated sequentially before potential dose escalation. The study aims to enroll 15 patients with an implantable cardioverter defibrillator and elevated arrhythmia risk. Initial data is expected next year, with TN-401 showing promise in normalizing heart rhythms and extending survival in preclinical models.

Maravai Lifesciences Holdings, Inc. (MRVI) stock rose 5.09% to $7.84 with a trading volume of 531,902 shares. The company reported revenue of $73.40 million, a net loss of $7.59 million, and an EPS of -$0.06. 73% of analysts recommend buying MRVI, with no sell recommendations. The biotech industry declined 0.20%, but stocks like Neurogene Inc. and Tenaya Therapeutics, Inc. gained. Maravai specializes in nucleic acid production, biologics safety testing, and protein detection.

Tenaya Therapeutics received DSMB clearance to escalate TN-201 dose in MyPeak-1 trial for MYBPC3-associated HCM, with no unexpected events reported. The trial now includes baseline biopsy, broader eligibility, and increased participant count, with detailed findings expected in December 2024.

Johns Hopkins Medicine scientists found that 30 days in space weakened human bioengineered heart tissues, leading to reduced beating strength and irregular rhythms compared to Earth-bound samples. The study expands understanding of low gravity's effects on astronaut health and may aid in studying heart muscle aging and therapeutics on Earth.

TN-201, a gene therapy for cardiomyopathy, is projected to generate $37 mn in annual revenue by 2038 in the US. Tenaya Therapeutics, the developer, uses a risk-adjusted NPV model (rNPV) to assess investment value, considering R&D costs and approval likelihood. The company reported operating and net losses of $131.2 mn and $124.1 mn respectively in FY2023.

Expert in IP strategy for FDA-approved drugs and clinical trials, with significant M&A experience in pharma. Represented numerous companies and investors in financings, IPOs, and IP diligence. Co-creator of healthcare investment initiatives and board member at LaunchBio.